Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC, Stereotactic Body Radiation Therapy (SBRT).
- Who it may be relevant to
- Registry conditions: Prostate Cancer. Basic parameters: 21 years — 90 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Single-Arm Phase II Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
Overview
This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.
Detailed description
Localized prostate cancer can be treated in 5 sessions using a precise, targeted form of radiation known as stereotactic body radiation therapy (SBRT), with low toxicity. Despite these advances, overall outcomes for aggressive (high risk) prostate cancer remain poor, with 10-year recurrence-free survival of approximately 65% regardless of treatment modality. Recurrences are typically distant and carry poor prognosis, with 5 year survival of 25%. The investigators propose to utilize the latest advances in cancer imaging (PSMA Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MR)) and radiation delivery (MR-guided radiation therapy with real-time adaptive planning), to deliver a personalized radiation treatment that targets the areas of greatest risk of recurrence in the prostate with improved precision, and as a result improve clinical outcomes for individuals with high risk prostate cancer. PSMA PET/MR is a novel imaging modality, not yet widely available, that augments the tissue detail provided by MR. The combination of PSMA PET with MR results in improved delineation of intraprostatic nodules and higher diagnostic accuracy for detection of metastatic disease compared to conventional imaging. PSMA PET/MR imaging data is readily transferable to a MR-based linear accelerator (MR-LINAC), a novel, innovative platform that allows direct visualization of the tumor during treatment, and permits real-time individualized correction for motion with online adaptive radiation planning.
Interventions
- Drug PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC
Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired. Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage. The PSMA PET/MR scan will be performed prior - Radiation Stereotactic Body Radiation Therapy (SBRT)
Patients will receive standard of care radiation therapy (SBRT)
Primary outcome measures
- Clinical efficacy of prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR), MR-Linear Accelerator (LINAC) will be assessed by evaluating recurrence free survival [Time frame: 24 months]
Secondary outcome measures (12)
- Performance of PSMA PET/MR to MR alone at staging prostate cancer [Time frame: Baseline]
- Performance of PSMA PET/MR to MR alone for identification of dominant intraprostatic nodules during radiation planning [Time frame: Baseline]
- Compare imaging biomarkers of interest on MR and PSMA PET/MR as predictors of treatment response, versus biopsy of treatment response and PSA [Time frame: Baseline]
- Compare imaging biomarkers of interest on MR and PSMA PET/MR as predictors of treatment response, versus biopsy of treatment response and PSA [Time frame: 12 months]
- Change in Quality of life questionnaires (EPIC-26) will be assessed. [Time frame: Baseline, 1month, 6months, 12 months, 18 months and 24 months.]
- Change in The American Urological Association (AUA) symptom score [Time frame: Baseline, 1month, 6months, 12 months, 18 months and 24 months.]
- Change in Number of Subjects with Adverse events [Time frame: Baseline, 1month, 6months, 12 months and 24 months.]
- The change in radiation doses received by the surrounding normal structures/PTV for each initial and adapted plan will be analyzed with a signed-rank Wilcoxon test (non-parametric test for paired comparisons). [Time frame: Baseline, 1month]
- Compare the changes in the Microbiome during SBRT-SIB [Time frame: Baseline]
- Compare the changes in the Microbiome during SBRT-SIB [Time frame: approx. 3 weeks]
- Compare the changes in the Microbiome during SBRT-SIB [Time frame: 12 months]
- Compare the immunological changes during SBRT-SIB [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- Male aged 21 years or older.
- Ability to provide signed informed consent and willingness to comply with protocol requirements.
- Pathologic confirmation of high-risk adenocarcinoma of the prostate gland as follows: a. Gleason 8-10 or tertiary component 5 disease and/or b. PSA of 20 ng/ml or greater and/or c. Tumor stage of T2c or greater; OR Unfavorable intermediate risk (Gleason 4+3=7, >50% of cores involved, or 2 or more intermediate risk factors which include Gleason 7 disease, PSA 10-20, or T2b disease)
- Participants must agree to use an acceptable form of birth control and utilize condoms for a period of seven days after each PSMA injection, if engaged in sexual activity.
- No evidence of metastatic disease, including pelvic lymph nodes.
Exclusion criteria
- Clinical and/or technical factors that would compromise statistical analysis of the PET and/or MR.
- Contraindications to PSMA IV administration
- Contraindications to prostate SBRT (history of transurethral resection of prostate; prostate size greater than 150 cc; AUA score greater than 20; history of prior radiation to the prostate)
- Other unspecified reasons that, in the opinion of investigators, make the subject unsuitable for enrollment
- Patients on or intending to take abiraterone will be excluded
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Weill Cornell Medicine — New York
Identifiers
NCT: NCT04402151 · 19-10020928 · R01CA249615